Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693640 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome
A Early Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT01693640: Completed Early Phase 1 study, sponsored by NYU Langone Health.
NCT01693640 is a Early Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01693640, a Early Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Hypothesis: Abatacept injections will decrease the number of oral ulcers seen in Behcet's patients
Primary Outcome
The primary endpoint is number of oral and genital ulcers (AUC) during the treatment period
Interventions
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-06 |
| Est. Completion | 2018-12-28 |
| Phase | Early Phase 1 |
What the finished NCT01693640 record still lists
NCT01693640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Abatacept is the first listed.
NCT01693640 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01693640 about?
NCT01693640 is a clinical study titled "A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome". Hypothesis: Abatacept injections will decrease the number of oral ulcers seen in Behcet's patients
What is the current status of trial NCT01693640?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2012-06. Estimated completion is 2018-12-28.
What interventions are being tested in trial NCT01693640?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT01693640?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01693640's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia